MedPlus Health Services Reports Drug License Suspension at Subsidiary Store in Telangana
MedPlus Health Services Limited disclosed that its subsidiary Optival Health Solutions Private Limited received a three-day drug license suspension for a store in Telangana. The order was issued by the Assistant Director, Drugs Control Administration, Warangal, under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of Rs 0.60 lacs from this regulatory action affecting the store at Parkal Main Road, Telangana.
*this image is generated using AI for illustrative purposes only.
MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting one of its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, its subsidiary, received a drug license suspension order for a store located in Telangana state.
Regulatory Action Details
The suspension order was issued by the Assistant Director, Drugs Control Administration, Warangal, Telangana, and was received by the company on March 28, 2026. The action specifically targets the store situated at Parkal Main Road, Telangana.
| Parameter: | Details |
|---|---|
| Issuing Authority: | Assistant Director, Drugs Control Administration, Warangal, Telangana |
| Nature of Action: | Suspension of Drug License for three days |
| Store Location: | Parkal Main Road, Telangana |
| Order Receipt Date: | March 28, 2026 |
| Legal Basis: | Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 |
Financial Impact
The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of Rs 0.60 lacs due to the three-day suspension of the drug license at the affected store location.
Compliance Disclosure
The disclosure was made under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, in its regulatory filing.
Public Availability
The company stated that the disclosure will be available on its official website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited. The filing was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on March 29, 2026.
Historical Stock Returns for Medplus Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.78% | +0.87% | -2.34% | +5.19% | +11.45% | -26.17% |
Will this regulatory action trigger increased scrutiny from drug control authorities across MedPlus's other store locations in Telangana and neighboring states?
How might this compliance issue affect MedPlus's expansion plans and new store licensing approvals in the region?
Could this incident impact MedPlus's relationships with pharmaceutical suppliers and affect inventory procurement terms?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
